CONNECT

ENVELOP a multi-part clinical research study for adults with different types of blood and bone marrow conditions called Myelofibrosis (MF), Essential thrombocythemia (ET), Polycythemia vera (PV) or Chronic myelomonocytic leukemia (CMML). This information will be focusing on two parts of the study, Parts 3 and 4. You can learn more about Parts 3 and 4 of the study by reviewing the information below.

Part 3: The main purpose of Part 3 is to understand the effects of the investigational medicine (navitoclax) on the heart (specifically electrocardiogram measurements).

Part 4: The main purpose of Part 4 of is to understand the effects of the investigational drug (navitoclax) on the metabolism (how the body changes food into energy) and pharmacokinetics (how much of the investigational drug is absorbed into the blood and how the body handles the investigational drug). In this study, navitoclax will be administered either given alone (Part 3) or in combination with the anti-inflammatory pain reliever drug Celecoxib (Celebrex) (Part 4) which will be given only on Days 1 and 7. The study is for individuals requiring new treatment when previous treatment did not work, could not be tolerated or the individual declined to receive standard treatments.

Eligibility Criteria

Part 3 and Part 4 (Participants in US and Europe):

  • Part 3 Only: At screening or baseline (pre-dose on Day 1), participant has QT interval corrected for heart rate (QTc) interval by Fridericia’s correction (QTcF) <=470 msec.
  • Participants with a documented diagnosis of primary or secondary MF, ET, PV or chronic myelomonocytic leukemia (CMML) as defined by the WHO classification.
  • Participants must be requiring treatment and have failed or are intolerant to at least one prior therapy or who refuse standard therapy.
  • ECOG performance status <= 2.
  • Must have adequate bone marrow, kidney, liver and hematology blood values as detailed in the study protocol

ENVELOP is a multi-part clinical research study for adults with Myelofibrosis (MF), Essential thrombocythemia (ET), Polycythemia vera (PV) or Chronic myelomonocytic leukemia (CMML). This information will be focusing on two parts of the study, Parts 3 and 4. You can learn more about Parts 3 and 4 of the study by reviewing the information below.

The study is for individuals requiring new treatment when previous treatment did not work, could not be tolerated or the individual declined to receive standard treatments. In addition to evaluating clinical outcomes with navitoclax monotherapy in these patients, Parts 3 and 4 will evaluate the following objectives:

Part 3: The main purpose of Part 3 is to understand the potential effect of navitoclax on the QT interval and other electrocardiogram measurements.

Part 4: The main purpose of Part 4 of is to understand the effects of the navitoclax on the pharmacokinetics and safety of a single dose of celecoxib (a CYP2C9 substrate).

Eligibility Criteria

  • Part 3 and Part 4 (Participants in US and Europe):
  • Part 3 Only: At screening or baseline (pre-dose on Day 1), participant has QT interval corrected for heart rate (QTc) interval by Fridericia’s correction (QTcF) <=450 msec.
  • Participants with a documented diagnosis of primary or secondary MF, ET, PV or chronic myelomonocytic leukemia (CMML) as defined by the WHO classification.
  • Participants must be requiring treatment and have failed or are intolerant to at least one prior therapy or who refuse standard therapy.
  • ECOG performance status <= 2.
  • Must have adequate bone marrow, kidney, liver and hematology blood values as detailed in the study protocol

Navitoclax, an investigational agent, is under clinical development and is not approved by regulatory health authorities. Safety and efficacy are under evaluation.

ClinicalTrials.gov Identifier: NCT04041050

This website uses cookies to ensure you get the best experience on our website. View Privacy Policy Here.

Do Not Agree
AGREE